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Human recombinant glutamate oxaloacetate
transaminase 1 (GOT1) supplemented with
oxaloacetate induces a protective effect after
cerebral ischemia
M Pérez-Mato1, P Ramos-Cabrer1, T Sobrino1, M Blanco1, A Ruban2, D Mirelman3, P Menendez4,5, J Castillo1 and F Campos*,1
Blood glutamate scavenging is a novel and attractive protecting strategy to reduce the excitotoxic effect of extracellular
glutamate released during ischemic brain injury. Glutamate oxaloacetate transaminase 1 (GOT1) activation by means of
oxaloacetate administration has been used to reduce the glutamate concentration in the blood. However, the protective effect of
the administration of the recombinant GOT1 (rGOT1) enzyme has not been yet addressed in cerebral ischemia. The aim of this
study was to analyze the protective effect of an effective dose of oxaloacetate and the human rGOT1 alone and in combination
with a non-effective dose of oxaloacetate in an animal model of ischemic stroke. Sixty rats were subjected to a transient middle
cerebral artery occlusion (MCAO). Infarct volumes were assessed by magnetic resonance imaging (MRI) before treatment
administration, and 24 h and 7 days after MCAO. Brain glutamate levels were determined by in vivo MR spectroscopy (MRS)
during artery occlusion (80 min) and reperfusion (180 min). GOT activity and serum glutamate concentration were analyzed
during the occlusion and reperfusion period. Somatosensory test was performed at baseline and 7 days after MCAO. The three
treatments tested induced a reduction in serum and brain glutamate levels, resulting in a reduction in infarct volume and
sensorimotor deficit. Protective effect of rGOT1 supplemented with oxaloacetate at 7 days persists even when treatment was
delayed until at least 2 h after onset of ischemia. In conclusion, our findings indicate that the combination of human rGOT1 with
low doses of oxaloacetate seems to be a successful approach for stroke treatment
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Stroke is a leading cause of mortality and morbidity in
developed countries, with increasing incidence because of
the progressive aging of the population. Pharmacological or
mechanical reperfusion therapy is the most effective treat-
ment during the acute phase of ischemic stroke and it is
associated with good outcome in 50–70% of cases. However,
these treatments are only applicable to o10% of patients
because of the short therapeutic window.1 Owing to these
therapeutic limitations, the development of new and effective
therapies to be used during the acute phase of ischemic
stroke is in high demand.
After ischemic stroke, there is a rapid but transient elevation
of glutamate into the extracellular space followed by a marked
increase in intracellular calcium, which provokes a neuronal
death through an excitotoxicity mechanism.2 Consequently,
calcium and glutamate antagonists have been widely studied
as protective agents in experimental models of cerebral
ischemia with encouraging results. Unfortunately, they failed
or displayed severe adverse effects when they were tested in
clinical trials.3 Nevertheless, because of the central role of
glutamate in the ischemic cascade, the mitigation of gluta-
mate excitotoxicity remains one of the most promising
strategies for the development of effective treatments to
minimize neurological damage following an acute ischemic
stroke. In this sense, novel therapeutic approaches should
aim at reducing the increased glutamate levels produced early
after the acute phase of ischemia.
Previous studies have shown that a decrease in blood
glutamate concentration leads to a larger natural glutamate
gradient between the brain and blood, facilitating the efflux of
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excess extracellular brain glutamate into the blood.4
Reduction in glutamate concentration in blood is induced
through the activity of the blood-resident enzyme glutamate
oxaloacetate transaminase 1 (GOT1), which catalyzes the
reversible transformation of oxaloacetate and glutamate
to aspartate and a-ketoglutarate. Thus, the increase in
the co-substrate (oxaloacetate) shifts the equilibrium of
the reaction to the right side, thereby decreasing the
blood glutamate concentration and lowering the brain
glutamate levels (see Teichberg et al.4 and Campos et al.5
for review).
Based on this mechanism, we6 and others4 have demon-
strated that the intravenous (i.v.) administration of oxaloace-
tate in a rat model of ischemia induced by transient occlusion
of the middle cerebral artery occlusion (MCAO) decreases the
glutamate concentration in blood and induces a lowering of
infarct volume and edema after ischemia. These effects were
also associated with a significant reduction in the sensor-
imotor deficit. To confirm that the protective effect was
mediated by a decrease in the brain glutamate levels, we
performed magnetic resonance spectroscopy (MRS) in the
infarct region. Spectroscopic analysis revealed that the
increase in brain glutamate seen in control animals after
MCAO was significantly reduced in animals treated with
oxaloacetate.4,6 These experimental results showed that
systemic reduction in glutamate concentration induced by
means of exogenous oxaloacetate administration could be
used as a novel and efficient protective strategy in ischemic
stroke. Importantly, however, the i.v. administration of
humans with oxaloacetate has potential serious limitations
as the required effective dosage of oxaloacetate in humans,
corresponding to that used in rats, might be toxic.7 In a
previous retrospective study with 4400 human patients, we
have found that ischemic patients with good outcome at 3
months after stroke, showed lower glutamate concentration
and higher GOT activity (418 U/l) in serum.8,9 Therefore, it is
tentative to postulate that treatments based on the
administration of recombinant GOT1 (rGOT1) alone or
supplemented with low doses of oxaloacetate could
improve the protective effects of oxaloacetate administered
on its own.
The purpose of this study was to analyze the protective
effect of oxaloacetate and human rGOT1 alone and in
combination with a low dose (non-effective dose) of oxaloa-
cetate in the rat model of ischemia induced by transient
MCAO, and to compare their effects with a control group
treated with saline.
Results
Animals included in the study. A total of 119 animals
were used in this study (Table I). Thirty-six animals were
used in the rGOT1 dose–response study, six animals per
group (six groups of treatments). In this study, no animal
deaths were observed within the first 24 h after treatments
administration. In the protective study, 60 animals were
included, six animals/group (four groups in the spectro-
scopic study and other six groups in the non-spectroscopic
study). Eighteen animals were excluded, 16 of them were
not included because of unsuccessful MCA occlusion or
reperfusion and two animals died 24 h after surgery (one
treated with saline and one treated with rGOT1). Finally, five
animals were used as sham-operated control rats (sham)
without MCAO.
Serum glutamate concentration is reduced by oxaloace-
tate and rGOT1 treatments in healthy animals. Adminis-
tration of saline (control group) did not affect (P¼ 0.373) the
basal concentration of glutamate during 24 h after the i.v.
administration (Figure 1a), demonstrating that the surgical
procedure did not interfere with the serum glutamate
concentration. Injection of glutamate (15 mM) induced
a significant (Po0.05) increase in serum glutamate
concentration 1 h after administration (Figure 1b). Basal
concentration was normalized 3 h after treatment admini-
stration. This effect shows that the administration of glutamate
in healthy animals could be used to simulate the increase in
serum glutamate, a hallmark biochemical parameter after
ischemia.
On the basis of previous reports where rGOT1 has been
used to study other pathologies,10,11 we started with a dose
of 6.44 mg per 100 g to analyze the capacity of the enzyme to
metabolize serum glutamate. Administration of 6.44 mg per
100 g rGOT1 induced a reduction (Po0.01) (Figure 1c)
in serum glutamate concentration with respect to the
maximum increase observed after glutamate injection.
The maximum effect appeared between 2 and 4 h after
administration of treatment. A higher dose of 12.88 mg per
100 g rGOT1 induced a robust reduction (Po0.01) in serum
glutamate concentration (Figure 1d). Similar to the previous
dose, the maximum lowering effect appeared between 2 and
4 h after administration of treatment; however, in this case,
the capacity to reduce serum glutamate concentration was
much higher. Administration of rGOT1 25.76 mg per 100 g
induced a significant (P¼ 0.007) reduction in serum gluta-
mate concentration (Figure 1e). The maximum effect
appeared between 2 and 4 h after administration of the
treatment; however, the capacity of this dose to reduce
serum glutamate concentration was similar to the 12.88 mg
per 100 g dose. These findings showed that 12.88 mg per
100 g seems to be the most appropriate dose of rGOT1 to
achieve a significant reduction in the serum glutamate
concentration in the animals. Of note, serum glutamate
concentrations were normalized 4–6 h after rGOT1 admin-
istration, demonstrating that the effect of the enzymatic
treatment is transient.
In order to determine whether the effect of the enzyme
could be potentiated by oxaloacetate (co-substrate of the
enzymatic reaction), the dose of rGOT1 (12.88 mg per
100 g) was supplemented with a non-effective dose of
oxaloacetate (1.5 mg per 100 g). In our previous study
(already published6), we had described that a dose of
1.5 mg per 100 g of oxaloacetate did not affect the serum
glutamate levels. Similar results were observed again
in this study (Figure 1f). Administration of rGOT1 12.88 mg
per 100 g with oxaloacetate (1.5 mg per 100 g) induced
an immediate and significant (Po0.01) lowering of
serum glutamate concentration, which is the gold
standard approach for reducing increased glutamate
levels after brain ischemia. The decrease in glutamate
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appeared 30 min (with respect to the basal values) after
treatment administration and remained during at least 3 h
(Figure 1g); however, no significant differences with
respect to rGOT1 12.88 mg pet 100 alone (Figure 1d) were
observed.
These results led us to examine whether the protective
efficacy of rGOT1 (12.88 mg per 100 g) or rGOT1 (12.88 mg per
100 g) supplemented with oxaloacetate (1.5 mg per 100 g) in
ischemic animals was higher than that observed previously6
with oxaloacetate 3.5 mg per 100 g.
Figure 1 Effect of rGOT and oxaloacetate (Oxal) on serum glutamate levels in healthy rats. Glutamate 15 mM was injected i.v. 30 min prior to treatments. (a) Rats treated
with saline (control group). (b) Rats treated with glutamate 15 mM. (c) Comparison between rats treated with glutamate 15 mM (blue line) and rats treated with glutamate 15 mM
and rGOT1 6.44mg per 100 g (black line). (d) Comparison between rats treated with glutamate 15 mM (blue line) and rats treated with glutamate 15 mM and rGOT1 12.88mg per
100 g (black line). (e) Comparison between rats treated with glutamate (15 mM) (blue line) and rats treated with glutamate (15 mM) and with rGOT1 (25.76mg per 100 g).
(f) Comparison between rats treated with glutamate 15 mM (blue line) and rats treated with glutamate (15 mM) and oxaloacetate (Oxal) (1.5 mg per 100 g). (g) Comparison
between rats treated with glutamate (15 mM) (blue line) and rats treated with glutamate (15 mM) and rGOT1 (12.88mg per 100 g) plus oxaloacetate (Oxal) (1.5 mg per 100 g).
Solid arrows denote the injection of glutamate. Dashed arrows indicate the injection of treatments. Serum samples were taken in basal conditions and 1, 2, 4, 6 and 24 h after
glutamate injection. Data are shown as mean±S.E.M. #Po0.05 compared to the basal levels; *Po0.05, **Po0.01 compared with animals treated with glutamate 15 mM
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rGOT1 with or without supplementation of oxaloacetate
induces a protective effect on ischemic animals. As it
was previously shown,6 MCAO induced an increase of 30%
of serum glutamate concentration 1 h after reperfusion
(Figure 2), returning to normal levels 3 h later. In sham-
operated rats in which MCA was not occluded, no changes in
plasma glutamate concentration were detected (data not
shown). The increase in serum glutamate concentration after
cerebral ischemia was inhibited (Po0.05) by each one of the
three treatments; rGOT1 (12.88 mg per 100 g), oxaloacetate
(3.5 mg per 100 g) and rGOT1 plus oxaloacetate (12.88 mg
per 100 gþ 1.5 mg per 100 g, respectively) (Figure 2). The
small differences observed between the treatments were not
statistically significant.
To confirm that treatment with rGOT1 induced an increase
in systemic GOT1 activity, their levels were measured at
different time points (Figure 3). GOT1 activities in the control
and oxaloacetate groups were not altered after treatment,
whereas rGOT1 treatments induced a significant (Po0.01)
increase in serum GOT activity 1 h after administration, which
returned close to normal levels 24 h after treatment
administration.
Quantitative analysis of MRS revealed a persistent
increase in brain glutamate levels after the occlusion of
MCA in the control group. Glutamate levels in the brain
parenchyma were significantly decreased (Po0.05 relative
to the control animals), with each of the three treatments
tested (Figures 4a and b). To demonstrate that the
reduction in serum and brain glutamate levels observed
after treatment administration leads to a protective effect in
our animal model of cerebral ischemia, infarct volumes
were measured at 24 h and 7 days after ischemia and were
compared with the control group. Figure 5a shows that,
although all treatments were able to induce a significant
(Po0.05) protection against the ischemic damage both 24 h
and 7 days after the onset of ischemia, rGOT1þ
oxaloacetate revealed to be the more effective treatment
(Po0.01, with respect to the control group). Analysis of
infarct volumes adjusted to the ipsilateral hemisphere
showed a similar protective profile (data not shown). Infarct
volumes measured in those animals subjected to the
spectroscopy protocol (Figure 5b) showed the same
protective results for the three treatments. Diffusion images
revealed that all animals subjected to spectroscopy
presented the same ischemic damage before the treatment
administration.
To determine the therapeutic window of rGOT1 treat-
ments, two groups of animals were treated 1 h after
reperfusion (140 min after occlusion). Analysis of serum
glutamate concentration in animals treated with rGOT1
(12.88 mg per 100 g) or rGOT1 plus oxaloacetate (12.88 mg
per 100 gþ 1.5 mg per 100 g, respectively) showed that
both treatments caused a significant (Po0.05) inhibition of
the increase in glutamate observed in the control group
(Figure 6). Analysis of infarct volume determined that both
treatments displayed similar infarct volume reduction at
24 h when administered immediately after reperfusion
(Figures 7a and b), however, while the protective effect
induced for rGOT1 disappears when this treatment is given
1 h after reperfusion on day 7; when rGOT1 is administered in
combination with oxaloacetate, the effect persists beyond 1 h
after reperfusion (Po0.05, with respect to the control).
Somatosensory test, an important end point assay of drug
screening in stroke, confirmed that reduction in infarct volume
observed with each of the three treatments was associated
with a better neurological outcome measured 7 days after
ischemia, showing the treatment rGOT1þ oxaloacetate to be
a superior effect (Po0.01, with respect to the control)
(Figure 8).
In vitro tests for neurotoxicity of oxaloacetate. To
determine the potential toxicity of oxaloacetate treatment
used in the study, a neuronal culture was exposed to a range
of concentrations of oxaloacetate (100 nM to 1 mM) during
48 h. Our analysis showed that, under these experimental
conditions, this compound did not affect the viability of the
neurons (Supplementary Figure I).
Figure 2 Time course of serum glutamate concentration (mM) in MCAO rats.
MCAO rats were treated with saline (control group) (n¼ 6), oxaloacetate (Oxal)
3.5 mg per 100 g (n¼ 6), rGOT1 12.88mg per 100 g (n¼ 6) and rGOT1 12.88 mg
per 100 g plus oxaloacetate 1.5 mg per 100 g (n¼ 6). Solid arrow indicates the time
of treatment injection, administered at the moment of reperfusion (80 min after
occlusion). Serum glutamate concentration was measured under basal conditions
(before surgery), at the moment of the reperfusion (before treatment administration),
and 1, 2 and 3 h after reperfusion. Data are shown as mean±S.E.M. *Po0.05,
**Po0.01 compared with control group
Figure 3 Time course of serum GOT activity in MCAO rats. MCAO rats were
treated with saline (control group) (n¼ 6), oxaloacetate (Oxal) 3.5 mg per 100 g
(n¼ 6), rGOT1 12.88mg per 100 g (n¼ 6) and rGOT1 12.88mg per 100 g plus
oxaloacetate 1.5 mg per 100 g (n¼ 6). Treatments were administered at the
moment of reperfusion (80 min after occlusion). GOT activity was measured under
basal conditions (before surgery), and 1, 3 and 24 h after reperfusion. Data are
shown as percentage compared with basal levels±S.E.M. **Po0.01 with respect
to control group
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Discussion
Nowadays, the concept of blood/brain glutamate scavenging
is well recognized as a novel and attractive protective strategy
to reduce the excitotoxic effect of excess extracellular
glutamate that accumulates in the brain following an ischemic
stroke. The efficacy of this strategy has been demonstrated in
different types of ischemic animal models, and it has also
been tested in other pathologies associated with an increase
in brain glutamate levels, such as traumatic brain injury (TBI)4
or glioma12 with successful results. GOT activation by means
of exogenous administration of oxaloacetate has been used
as the most common approach to reduce the serum glutamate
concentration. In this study, we found that the i.v. administra-
tion of rGOT1 was also able to induce a reduction in serum
and brain glutamate levels, which also resulted in a significant
reduction in the infarct volume and improvement in the
sensorimotor deficit after ischemia. These effects were similar
to those observed with the higher doses of oxaloacetate.6
Importantly, the protective effect of rGOT1 was more evident
when it was administered in combination with a low
concentration of oxaloacetate that had no effect by itself,
indicating that the combined administration of rGOT1 and
oxaloacetate could be an efficient serum glutamate-scaven-
ging approach. The i.v. administration of an endogenous
serum enzyme such as GOT1 as a new protective treatment
against ischemia is an interesting strategy because it is
unlikely that the administration of rGOT1 can induce toxic
effects in humans as the levels of this enzyme varies among
healthy human subjects (7–45 U/l), and has been shown to
increase 410-fold in patients with liver damage.13 On the
other hand, the increase in the enzyme activity after the
treatment is not much longer than 24 h, and serum glutamate
concentrations come back to normal within the first 6 h, which
reduces long-term potential adverse effects. However, the
effective dose of GOT (12.88mg per 100 g) used in the animals
cannot be extrapolated to humans, as GOT levels in rats are
almost 10-fold higher than those in humans (10 U/l in humans
versus 95 U/l in rats). In this regard, further (pre)-clinical
studies based on the administration of GOT should be
conducted in humans to determine the effective therapeutic
dose of GOT able to induce a significant reduction in serum
glutamate in humans. In line with this, we have previously
observed that stroke patients who had high GOT activity
(average of 17 U/l) at admission had reduced serum gluta-
mate concentrations and a significantly better neurological
outcome than patients with lower average activity of GOT of
11 U/l.8,9 Therefore, it can be hypothesized that the adminis-
tration of rGOT1 doses able to increase the systemic GOT
activity, at least two or three-fold, are necessary for clinical
studies in stroke patients.
Regarding the use of oxaloacetate as a serum glutamate-
scavenging treatment, such a treatment could present
some limitations associated with the high dose likely to
be necessary in patients to achieve the same effects than those
observed in experimental animals.7 However, although to date
there are no consistent data in humans confirming this toxic
effect, a study published in the 60’s,14 in which oxaloacetate
was used to treat diabetic patients (from 200 to 1000 mg per
day in three divided doses given orally) did not report any effect
on liver function tests and blood acetone and cholesterol levels
at the doses administered. Oral administration is not compar-
able to i.v. administration used in this study; nevertheless, this
clinical study represents evidence for the relative safety of the
administration of this molecule in humans. In this line, we also
observed that oxaloacetate does not affect the viability of the
neuronal culture, which is used as a current assay for
neurotoxicity.10 The protective effects of oxaloacetate have
also been discussed.5 As this molecule participates in the
energy metabolism and provides an antioxidant protection of
cells subjected to stress, such as hydrogen peroxide, it has
been suggested that the protective role of oxaloacetate could
be related to other mechanisms different from serum glutamate
reduction. Studies in a TBI model showed that the protective
effect of oxaloacetate was abolished in the presence of excess
glutamate in serum or when it was administered in combination
with maleate (a GOT inhibitor),15 which effectively demon-
strates its serum glutamate-scavenging action.
Figure 4 MRS analysis. (a) Quantitative analysis of glutamate signals were
normalized to creatine (Cr) peaks for each single spectra. Brain glutamate levels
were analyzed during the occlusion (80 min) and during reperfusion (180 min). Brain
glutamate levels were similar in treated (before treatment) and control (treated with
saline) ischemic animals during occlusion. However, during reperfusion glutamate
levels were lower in treated animals compared with the control. (b) Time course of
brain glutamate levels in MCAO rats treated with saline (control group) (n¼ 6),
oxaloacetate (Oxal) 3.5 mg per 100 g (n¼ 6), rGOT1 12.88mg per 100 g (n¼ 6)
and rGOT1 12.88mg per 100 g plus oxaloacetate 1.5 mg per 100 g (n¼ 6). Solid
arrow indicates the moment of i.v treatment. Cerebral glutamate levels were
measured during occlusion (80 min) and reperfusion (180 min). MRS analysis was
performed in an independent group of animals. Data are shown as the mean of
cerebral glutamate levels relative to the contralateral region±S.E.M. Blue dashed
line indicates the levels of brain glutamate in the contralateral region. *Po0.05,
**Po0.01 compared with control group
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M Pérez-Mato et al
5
Cell Death and Disease
Interestingly, the protective effect of rGOT1 (12.88mg per
100 g) was potentiated when it was administered in combina-
tion with a non-effective low dose of oxaloacetate (1.5 mg per
100 g) but not with higher doses of the enzyme (25.76 mg per
100 g). These findings are in agreement with a previous
glioblastoma study reporting that the combination of rGOT1
with low amounts of oxaloacetate together with temozolodine
significantly extends the lifespan of tumor-bearing animals.12
The therapeutic synergistic effect observed between oxaloa-
cetate and GOT can be attributed to the fact that the
endogenous oxaloacetate concentration can become a
limiting factor of the enzymatic reaction when GOT activity
is increased after treatment. Therefore, attending to the rapid
and maintained reduction in serum glutamate concentration,
treatments based on the combined administration of rGOT1
supplemented with a low concentration of oxaloacetate could
be optimal to reach the maximum protective effect in
ischemia. Of note, the low dose of oxaloacetate is sufficient
to increase the glutamate-scavenging activity of rGOT1,
which reduces the potential complications associated with a
high dose of this molecule.
It is crucial to develop treatment approaches capable of
overcoming the narrow therapeutic window in stroke in order to
mitigate the detrimental effects of the excess of brain glutamate
after ischemia, which represents a stumbling-block from a
clinical point of view. Owing to this limitation, only those
treatments (mainly, NMDA antagonists) with protective effects
beyond the first 1–2 h after the onset of ischemia have shown
clinical interest.3 In our ischemic experimental model, we have
observed that brain and serum glutamate levels appear to be
increased in the first 2 h after reperfusion. We observed that
lowering of glutamate by means of GOT treatments had
protective effects even when the treatment was delayed until
1 h after reperfusion. Further experiments need to be carried
out to determine the length of the therapeutic window; however,
based on our results, it may be speculated that the therapeutic
window for the administration of rGOT1 could be up to 2 h after
the onset of ischemia. As this treatment does not require a prior
computerized tomography scan, it could be given as early as
possible, perhaps even as ambulatory treatment suggesting
potential clinical application. In comparison with previous
glutamate antagonists, another important advantage of
Figure 5 Infarct size assessed by means of MRI in MCAO rats. MCAO rats were treated with saline (control group), oxaloacetate (Oxal) 3.5 mg per 100 g, rGOT1 12.88 mg
per 100 g and rGOT1 12.88mg per 100 g plus oxaloacetate 1.5 mg per 100 g. Treatments were administered at the moment of the reperfusion. Infarct size was assessed in
ischemic rats not subjected to spectrocopy analysis (a) as well as in ischemic rats subjected to spectroscopy analysis (b). Infarct sizes were measured at 24 h and 7 days after
ischemia. Only those animals subjected to spectroscopy analysis presented ADC basal volumes (determined before the administration of treatment). Data are shown as the
mean of infarct volume (mm3)±S.E.M in a, and percentage relative to the basal volume in b. *Po0.05, **Po0.01 with respect to the control group at 24 h; #Po0.05,
##Po0.01 as well as on day 7
Figure 6 Time course of serum glutamate concentration (mM) in MCAO rats.
MCAO rats were treated with saline (control group) (n¼ 6), rGOT1 12.88mg per
100 g (n¼ 6) and rGOT1 12.88mg per 100 g plus oxaloacetate 1.5 mg per 100 g
(n¼ 6) 1 h after reperfusion. Solid arrow indicates the time of the i.v. treatments.
Serum glutamate concentration was measured under basal conditions (before
surgery), at the time of reperfusion (before treatment administration), and 1, 2 and
3 h after reperfusion. Data are shown as mean±S.E.M. *Po0.05, **Po0.01 with
respect to the control group
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serum-scavenging-based treatments is that their effects are
not mediated through the neuronal ionotropic glutamate
receptors, thereby avoiding problems of poor blood–brain
barrier permeability and potential neurotoxic effects.
In conclusion, in this study we show that oxaloacetate
potentiates the protective effect of intravenously administered
rGOT1 after ischemia. This effect is mediated through a
reduction in serum and brain glutamate levels. The protective
effect was observed even when the treatments were initiated
as soon as 2 h after the onset of ischemia. The robust
protection shown by the combination of rGOT1 and low doses
of oxaloacetate proposes that this strategy may represent a
valid approach for a successful acute-phase stroke treatment.
Materials and Methods
Animals. Experimental protocols were approved by the local Animal Care
Committee according to the European Union (EU) rules (86/609/CEE, 2003/65/CE
and 2010/63/EU). Male Sprague–Dawley rats (Harlan Laboratories, Barcelona,
Spain) with a weight of 250–300 g were used. Rats were watered and fed ad
libitum. Anesthesia was induced by inhalation of 5% sevoflurane in a nitrous oxide/
oxygen mixture (70/30). Rectal temperature was maintained at 37±0.5 1C by
using a feedback-controlled heating pad. Glucose levels were analyzed before
surgery (ranging from 180 to 220 mg/dl).
Surgical procedures. Transient focal ischemia was induced in rats by using
the transient MCAO following the surgical procedures previously described.6
In brief, under an operating microscope, the left common, external and internal
carotid arteries were dissected from connective tissue through a midline neck
incision. The left external carotid artery and pterygopalatine artery of the internal
carotid artery were separated and ligated by 5–0 silk sutures. A 23-mm segment of
3–0 nylon monofilament suture with the tip rounded by heat was inserted into the
stump of the left common carotid artery and advanced into the internal carotid
artery to 20 mm from the bifurcation to occlude the origin of the MCA. The suture
was removed after 80 min of occlusion. A laser-Doppler flow probe (tip diameter
1 mm) attached to a flowmeter (PeriFlux 5000; Perimed AB, Stockholm, Sweden)
was located over the thinned skull in the MCA territory (4 mm lateral to bregma) to
obtain a continuous measure of relative cerebral flow during the experiment. Only
animals with a cerebral serum flow reduction of over 70% and with reperfusion
after occlusion were included in the study. Experimental procedures were
performed following five criteria derived from the Stroke Therapy Academic
Industry Roundtable (STAIR) group guidelines for preclinical evaluation of stroke
therapeutics:11,16 (1) cerebral serum flow was measured to confirm the vascular
occlusion as an index of the reliability of the ischemic model; (2) animals were
randomly assigned to treatment groups of the study; (3) researchers were blinded
to treatment administration; (4) researchers were blinded to treatments during
outcome assessment; and (5) temperature was controlled during the ischemic
period.
Experimental protocol. In our previous study, we demonstrated that an i.v.
dose of 3.5 mg per 100 g (weight of animal) of oxaloacetate induced a significant
reduction in serum glutamate concentration, whereas a dose 1.5 mg per 100 g
Figure 7 Infarct size assessed by means of MRI in MCAO rats. MCAO rats were treated at two different times. (a) saline (control group) (n¼ 6), rGOT1 12.88mg per
100 g (rGOT1) (n¼ 6) at the moment of reperfusion, and rGOT1 12.88mg per 100 g (rGOT1þ 1 h) (n¼ 6) 1 h after reperfusion. (b) Saline (control group) (n¼ 6), rGOT1
12.88mg per 100 g plus oxaloacetate 1.5 mg per 100 g (Oxalþ rGOT1) (n¼ 6) at the time of the reperfusion and rGOT1 12.88 mg per 100 g plus oxaloacetate 1.5 mg per
100 g (Oxalþ rGOT1 þ 1 h) (n¼ 6) 1 h after reperfusion. Data are shown as the mean of infarct volume (mm3)±S.E.M. *Po0.05, **Po0.01 compared with control group at
24 h; #Po0.05, ##Po0.01 with respect to control group at day 7
Figure 8 Effect of treatments on somatosensory test. Sensorimotor deficits
after an ischemic insult were assessed using the cylinder test and quantified by
laterality index. þ 1 h denotes that those treatments were administered 1 h after
reperfusion. Other treatments were administered at the moment of the reperfusion.
Somatosensory tests were performed 1 day before surgery (baseline) and on day 7
after MCAO. Values represent the mean±S.E.M, n¼ 6. *Po0.05, **Po0.01
relative to control group
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(low dose) was found to be ineffective.6 However, as a dose–response study on
the effect of the i.v. administration of rGOT1 on serum glutamate concentration
has not been yet tested, we divided our study into two steps: (A) a rGOT1 dose–
response study and (B) protective study.
(A) rGOT1 dose–response study: here, healthy rats were first subjected to an
artificial increase in serum glutamate concentration to determine the effective dose
of rGOT1 able to induce a reduction in glutamate concentration (n¼ 6 per dose).
The artificial increase in serum glutamate concentration was induced by means of
the administration of glutamate 15 mM (1 ml per 300 g weight of the animal). This
procedure was used to mimic the increase in serum glutamate observed after an
ischemic insult. Glutamate 15 mM was injected at the beginning of the experiment
(after animal anesthesia induction), and 30 min later rGOT1 was given. Serum
samples (500ml) were taken (from vein tail) under basal conditions (before
glutamate injection), and 1, 2, 4, 6 and 24 h after glutamate injection. Treatments
were administered through the jugular vein in a bolus form. All rGOT1 doses were
dissolved in saline (0.9% of NaCl) and the concentration was adjusted to inject 1 ml
per animal. pH was adjusted to 7.4. Pure human rGOT1 (5800 U/l, analyzed with
Reflotron GOT (aspartate transaminase, AST) Test) was provided by Professor
David Mirelman from Weizmann Institute, Israel.
(B) Protective study: in this phase, the protective effects of oxaloacetate 3.5 mg
per 100 g (weight of animal) and the optimal doses selected in rGOT1 dose–
response study were tested in an ischemic model. To determine the protective effect
of the treatments, brain and serum glutamate levels, serum GOT activity, infarct
volume and functional deficit were measured in the experimental animals.
Treatments were administered immediately after reperfusion (80 min after
occlusion) or 1 h after reperfusion (140 min after occlusion).
Brain glutamate levels were measured during occlusion (80 min) and during
reperfusion (180 min) using the MRS technique. Serum glutamate concentration
was determined under basal conditions (before surgery), immediately after
reperfusion (80 min after occlusion) and 1, 2 and 3 h after reperfusion. GOT activity
was measured under basal conditions (before surgery) and 1, 3 and 24 h after
reperfusion. As it was not technically accurate to measure the serum and brain
glutamate levels after reperfusion at the same time in the same animal, treatments
were tested in two independent groups of animals (n¼ 6 each). One group was
used to measure brain glutamate levels and the other to determine the serum
glutamate concentration and GOT activity. Infarct volume was determined during
occlusion (only in those animals subjected to spectroscopy analysis), 24 h and 7
days after ischemia. Sensorimotor test was performed under basal conditions (1 day
before surgery) and 7 days after ischemia.
Serum glutamate analysis. Serum samples were collected in test tubes,
centrifuged at 3000 r.p.m. for 7 min, serum was removed and immediately frozen
and stored at –80 1C. Serum glutamate concentration was determined by means
of Glutamate Assay Kit (Abnova, Taipei City, Taiwan) following the manufacturer’s
technical specifications.
Serum GOT activity analysis. GOT activity was determined by means of
Reflotron GOT (AST) Test following the manufacturer’s technical specifications
(Roche, Basel, Switzerland).
Magnetic resonance imaging protocol. Infarct size was assessed by
means of magnetic resonance imaging (MRI). MRI studies were conducted on a
9.4-T horizontal bore magnet (Bruker BioSpin, Ettligen, Germany) with 12 cm wide
actively shielded gradient coils (440 mT/m). Radiofrequency (RF) transmission was
achieved with a birdcage volume redsonator; signal was detected using a four-
element arrayed surface coil, positioned over the head of the animal, which was
fixed with a teeth bar, earplugs and adhesive tape. Transmission and reception
coils were actively decoupled from each other. Gradient-echo pilot scans were
performed at the beginning of each imaging session for accurate positioning of
the animal inside the magnet bore. Apparent diffusion coefficient (ADC) maps
were acquired during MCA occlusion (80 min after the onset of ischemia) using a
spin-echo echo-planar imaging sequence with the following acquisition
parameters: field-of-view 19.2 19.2 mm2, image matrix 128 128 (in-plane
resolution 0.15 mm/pixel), 14 consecutive slices of 1 mm thickness, repetition
time¼ 4 s, echo time¼ 30 ms and diffusion b values: 0, 100, 300, 600, 800, 1000
and 1400 s/mm2. T2-weighted image was acquired 24 h and 7 days after the onset
of ischemia. All images were processed and maps were constructed with ImageJ
(Rasband WS, ImageJ, US National Institutes of Health, Bethesda, MD, USA,
http://rsb.info.nih. gov/ij/, 1997–2009).
In vivo MRS. MRS was acquired as previously described.17,18 Local shimming
was performed by manual adjustment of first- and second-order shim coil currents
using a proton-stimulated-echo acquisition mode (STEAM)-waterline sequence.
The field homogeneity in a 3-mm3 voxel typically resulted in signal line widths of
10–20 Hz for the water signal. Water signal was suppressed by variable power RF
pulses with optimized relaxation delays (VAPOR). In vivo 1 H magnetic resonance
spectra of the rat brain were acquired by using a STEAM sequence with echo
time¼ 3 ms, mixing time (TM)¼ 5 ms, repetition time¼ 2500 ms, 176 averages,
cubic voxel¼ 3 3 3 mm3 (27ml). Spectra were processed using MNOVA 7
(Mestrelab Research, Santiago de Compostela, Spain). For the quantitative
analysis, glutamate signals were normalized to the creatine peak areas for each
single spectrum (Supplementary Figure II). MRS was acquired during the
occlusion (80 min) and during 180 min after reperfusion.
Image analysis. All images were processed using ImageJ (Rasband WS,
ImageJ, NIH, http://rsb.info.nih.gov/ij). Infarct volumes were determined from
(ADC maps) and T2-weighted images by manually selecting areas of reduced
ADC values or hyperintense T2 signal by a researcher blinded to the animal
protocols.
Sensorimotor test. Sensorimotor deficits after ischemic insult were
assessed using the cylinder test as previously described.19 This test consists
of evaluation of asymmetry of limbs during the exploratory activity. For this test,
the animal was put in a cylinder of transparent base of 20 cm diameter. A video
camera is located under this transparent cylinder for recording the vertical
exploratory movement of the animal with anterior limbs during 2–10 min,
depending on movement grade. For recording analysis, the VirtualDub software
was used. Analyzed behaviors were as follows: number of times that the animal
touches the cylinder wall and independent use of each limb in contact with the
cylinder wall in each upward movement. Laterality index was calculated
(the number of times that the animal touches the cylinder with the right leg
during the ascendant movement by the number of times that the animals touch with
each leg). This index is close to 0.5 for healthy animals and tends to be 0 or 1 for
animals that have a preferential use of the left or the right paw, respectively.
Somatosensory tests were performed 1 day before MCAO and on day 7 after
ischemia during the darkness cycle.
Primary culture of rat cortical neurons. Primary cultures of cortical
neurons were performed as described previously.20 Brains were removed from
fetal Sprague–Dawley rats (Harlan Laboratories, Barcelona, Spain) on embryonic
day 18, and the cortical area was dissected. Neurons were mechanically
dissociated in incubation medium consisting of 80% Eagle’s minimum essential
medium (MEM) containing 0.6% glucose, 0.029% glutamine, 16 mg/l gentamicin,
10% horse serum and 10% fetal calf serum. The dissociated neurons were plated
at a density of 100 000 cells per well in poly-lysine-precoated 24-multiwell plates.
Medium was replaced twice weekly and studies were performed at in vitro on day 8,
when the cultures consisted of Z95% neurons.
Neuronal toxicity MMT assay. After 8 days in culture, neurons were
exposed to different concentrations of oxaloacetate. Cell death was quantified with
thiazolyl blue tetrazolium bromide (MTT) (Sigma, St. Louis, MO, USA) 48 h later.
Neurons were incubated in 200mg/ml MTT at 37 1C, and after 2 h, the culture
medium was aspirated and cells were lysed in 250ml DMSO. Color intensity was
measured at 570 nm. Results were expressed as the percentage of absorbance of
control wells. Vehicle treatment was used in control group and DMSO 2%
treatment for control death.
Statistical analysis. Results were expressed as mean±S.E.M. Statistical
analyses were performed using one-way ANOVA followed by a Bonferroni post
hoc analysis to determine between-group differences. A P-value o0.05 was
considered as statistically significant. The statistical analysis was conducted using
PASW Statistics 18 for Mac (SPSS Inc., Chicago, CA, USA).
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